Related Experiment Video
Updated: Jun 21, 2026

Expression, Purification, Crystallization, and Enzyme Assays of Fumarylacetoacetate Hydrolase Domain-Containing Proteins
Published on: June 20, 2019
Expression and characterization of CYP4V2 as a fatty acid omega-hydroxylase
Mariko Nakano1, Edward J Kelly, Allan E Rettie
1Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, WA 98195-7610, USA.
Abstract:
Bietti's crystalline dystrophy is an ocular disease that is strongly associated with polymorphisms in the CYP4V2 gene. CYP4 enzymes are typically microsomal fatty acid omega-hydroxylases that function together with mitochondrial and peroxisomal beta-oxidation enzymes to degrade cellular lipids. Indeed, ocular and peripheral cells cultured from patients with Bietti's have been reported to exhibit abnormal lipid metabolism. However, CYP4V2 possesses low sequence homology to other members of the CYP4 family. Therefore, we cloned and expressed CYP4V2 and analyzed the functional characteristics of this new cytochrome P450 enzyme. We find that CYP4V2 is a selective omega-hydroxylase of saturated, medium-chain fatty acids with relatively high catalytic efficiency toward myristic acid. Moreover, N-hydroxy-N'-(4-n-butyl-2-methylphenyl formamidine) (HET0016) is a nanomolar inhibitor of the enzyme. Therefore, CYP4V2 exhibits catalytic functions typical of a human CYP4 enzyme, but with a distinctive chain-length selectivity coupled with high omega-hydroxylase specificity. Consequently, defective omega-oxidation of ocular fatty acids/lipids secondary to mutations in the CYP4V2 gene appears to be a plausible mechanism underlying Bietti's crystalline dystrophy.
Insights
Bietti's crystalline dystrophy is linked to the CYP4V2 gene. This study reveals CYP4V2 functions as a specific omega-hydroxylase, suggesting its defect causes this ocular disease.
Area of Science:
- Biochemistry
- Genetics
- Ophthalmology
Background:
- Bietti's crystalline dystrophy is an inherited ocular disease.
- Genetic variations in the CYP4V2 gene are strongly associated with this condition.
- Abnormal lipid metabolism is observed in patients' cells.
Purpose of the Study:
- To clone and functionally characterize the CYP4V2 gene product.
- To investigate the enzymatic activity and substrate specificity of CYP4V2.
- To elucidate the role of CYP4V2 in the pathogenesis of Bietti's crystalline dystrophy.
Main Methods:
- CYP4V2 gene cloning and expression in a suitable system.
- Enzymatic assays to determine substrate specificity and catalytic efficiency.
- Inhibition studies using specific enzyme inhibitors like HET0016.
Main Results:
- CYP4V2 was identified as a selective omega-hydroxylase for saturated, medium-chain fatty acids.
- The enzyme exhibits high catalytic efficiency, particularly towards myristic acid.
- HET0016 was found to be a potent nanomolar inhibitor of CYP4V2 activity.
Conclusions:
- CYP4V2 possesses unique omega-hydroxylase activity with distinct chain-length selectivity.
- Defective omega-oxidation of ocular lipids due to CYP4V2 mutations is a likely cause of Bietti's crystalline dystrophy.
- This research provides a molecular basis for understanding the disease mechanism.
Related Concept Videos
Lipid Catabolism
Overview of Fatty Acid Metabolism
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Structure of Lipids
Structure of Lipids
Structure of Lipids
Biosynthesis of Lipids
